GlobeNewswire PharmaOriginal article
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
Data ReadoutpositivePRPDaraxonrasibPositive
AI Analysis
Summary
Propanc Biopharma reported preclinical data showing 90% tumor growth inhibition with PRP in pancreatic cancer models, highlighting advantages over Revolution Medicines' daraxonrasib including reduced metastases and chemo re-sensitization.
Outcome Details
90% tumor growth inhibition in pancreatic cancer models with deep tumor control, fewer metastases, less fibrotic microenvironment, and chemo re-sensitization
Importance:5/10
Sentiment:
0.70
preclinical datapancreatic cancerRAS inhibitortumor growth inhibitioncompetitive comparison
Related Companies
Read the original article
Published by GlobeNewswire Pharma on October 7, 2026 12:30 PM